ES2144792T3 - Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis. - Google Patents

Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis.

Info

Publication number
ES2144792T3
ES2144792T3 ES96940912T ES96940912T ES2144792T3 ES 2144792 T3 ES2144792 T3 ES 2144792T3 ES 96940912 T ES96940912 T ES 96940912T ES 96940912 T ES96940912 T ES 96940912T ES 2144792 T3 ES2144792 T3 ES 2144792T3
Authority
ES
Spain
Prior art keywords
nadph oxidase
prevention
atherosclerosis
medication
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96940912T
Other languages
English (en)
Inventor
James A Holland
David K Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Application granted granted Critical
Publication of ES2144792T3 publication Critical patent/ES2144792T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)

Abstract

SE PROPORCIONA UN METODO PARA LA PREVENCION Y EL TRATAMIENTO DE LA ATEROSCLEROSIS Y ENFERMEDADES RELACIONADAS EN MAMIFEROS, EN EL QUE SE ADMINISTRA UN INHIBIDOR DE LA NADPH OXIDASA. EL INHIBIDOR DE LA NADPH OXIDASA PREVIENE LA PRODUCCION DE ESPECIES DE OXIGENO REACTIVO ANTE LA EXPOSICION DE LAS CELULAS ENDOTELIALES A NIVELES ATEROGENICOS DE LDL, DANDO LUGAR ASI A UNA DISMINUCION DE LA ENDOCITOSIS Y LA HIPERPERMEABILIDAD VASCULAR. LOS INHIBIDORES PREFERIDOS DE LA NADPH OXIDASA SON LOS CORRESPONDIENTES A LA FORMULA (I). ADEMAS, SE PROPORCIONA UN METODO DIAGNOSTICO PARA PREDECIR EL RIESGO DE ENFERMEDADES ATEROSCLEROTICAS PARA UN PACIENTE HUMANO.
ES96940912T 1995-11-27 1996-11-27 Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis. Expired - Lifetime ES2144792T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/562,767 US5763496A (en) 1995-11-27 1995-11-27 Prevention of atherosclerosis using NADPH oxidase inhibitors

Publications (1)

Publication Number Publication Date
ES2144792T3 true ES2144792T3 (es) 2000-06-16

Family

ID=24247689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96940912T Expired - Lifetime ES2144792T3 (es) 1995-11-27 1996-11-27 Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis.

Country Status (10)

Country Link
US (2) US5763496A (es)
EP (2) EP0861070B1 (es)
JP (2) JPH11507946A (es)
AT (1) ATE189957T1 (es)
AU (1) AU1085997A (es)
CA (1) CA2238098C (es)
DE (1) DE69606882T2 (es)
ES (1) ES2144792T3 (es)
GR (1) GR3033067T3 (es)
WO (1) WO1997019679A2 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090851A (en) * 1997-09-10 2000-07-18 Johns Hopkins University School Of Medicine Use of an NADPH-oxidase inhibitor in the treatment of reperfusion injury
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
NZ509803A (en) * 2000-02-09 2001-08-31 Paul A Treatment of fibromyalgia with ubiquinone 10 and succinic acid
WO2001089517A2 (en) * 2000-05-19 2001-11-29 Thomas Jefferson University Inhibition of cell proliferation and matrix synthesis by antioxidants and nad(p)h oxidase inhibitors
US6492429B1 (en) * 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
AU2001296821A1 (en) * 2000-10-12 2002-04-22 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
EP1353676A4 (en) * 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
DE10104825A1 (de) * 2001-02-01 2002-08-08 Florian Lang Screening von Antimalariamitteln
US7202030B2 (en) * 2001-11-01 2007-04-10 Rensselaer Polytechnic Institute Solid-phase array-based biocatalytic transformations
AU2002359790A1 (en) * 2001-12-21 2003-07-15 Charlotte Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Regulation of nad(p)h oxidase growth and transcription in melanoma cells
US6949586B2 (en) * 2002-02-11 2005-09-27 Council Of Scientific Research Synergistic composition of trans-tetracos-15-enoic acid and Apocynin and method of treatment for hepatotoxicity
EP1499742B1 (en) * 2002-04-17 2010-11-03 Glucox Biotech AB Nad(p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
EP1509618B1 (en) * 2002-05-13 2008-08-20 Arexis AB Autoimmune conditions and nadph oxidase defects
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
WO2004069201A2 (en) * 2003-02-03 2004-08-19 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
AU2004216541A1 (en) * 2003-02-28 2004-09-10 Howard Florey Institute Of Experimental Physiology And Medicine Therapeutic compositions
US20070092551A1 (en) * 2003-05-02 2007-04-26 Takara Bio Inc. Therapeutic agent
WO2005103297A1 (en) * 2004-03-31 2005-11-03 Georgetown University METHODS AND COMPOSITIONS RELATED TO MODULATION OF p22phox
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
US20070254900A1 (en) * 2004-08-11 2007-11-01 Kassab Ghassan S Treatments for Congestive Heart Failure
US8569374B2 (en) 2004-09-16 2013-10-29 The Trustees Of The University Of Pennsylvania NADPH oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20080051451A1 (en) * 2006-03-15 2008-02-28 Marcel Linschoten Autoimmune conditions and NADPH oxidase defects
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
KR100989093B1 (ko) * 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
PT2334295T (pt) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
SI2424356T1 (en) 2009-04-29 2018-01-31 Armarin Pharmaceuticals Ireland Limited A stable pharmaceutical composition and procedures for its use
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
WO2010147994A1 (en) 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
WO2013136277A1 (en) 2012-03-13 2013-09-19 Unimark Remedies Ltd. Pharmaceutical compositions for treatment of cardiovascular diseases
US20140080850A1 (en) * 2012-06-05 2014-03-20 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
EP3815684B1 (en) 2012-06-29 2024-09-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
WO2014183184A1 (en) * 2013-05-14 2014-11-20 University Of Prince Edward Island Compositions and methods for treating cardiometabolic diseases and disorders
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
EP3034500A1 (en) 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
AU2017318672B2 (en) 2016-09-01 2022-03-10 Nutrition 21, Llc Magnesium biotinate compositions and methods of use
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
ES2983568T3 (es) 2018-09-24 2024-10-23 Amarin Pharmaceuticals Ie Ltd Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto
WO2020092431A1 (en) 2018-11-02 2020-05-07 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
WO2021127048A1 (en) 2019-12-16 2021-06-24 Nutrition 21, Llc Methods of production of arginine-silicate complexes
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593966A (en) * 1989-03-31 1997-01-14 The United States Of America As Represented By The Department Of Health And Human Services Peptide derivatives of cytochrome b558 and their use as medicaments
DE4109627A1 (de) * 1991-03-23 1992-09-24 Boehringer Mannheim Gmbh Neue phenolether, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
GB9200623D0 (en) * 1992-01-13 1992-03-11 Bayer Ag Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
JPH06135880A (ja) * 1992-10-30 1994-05-17 Kanebo Ltd 活性酸素消去剤
JP3023254B2 (ja) * 1992-11-05 2000-03-21 鐘紡株式会社 メラニン生成抑制剤
JPH06227977A (ja) * 1993-02-01 1994-08-16 Suntory Ltd 活性酸素消去剤
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
JPH07165575A (ja) * 1993-12-08 1995-06-27 Nippon Oil & Fats Co Ltd ヒドロキノン誘導体
JP2774063B2 (ja) * 1993-12-24 1998-07-09 鐘紡株式会社 抗酸化組成物

Also Published As

Publication number Publication date
DE69606882T2 (de) 2000-08-17
EP0861070A2 (en) 1998-09-02
EP0861070B1 (en) 2000-03-01
US5902831A (en) 1999-05-11
WO1997019679A2 (en) 1997-06-05
EP0914821A3 (en) 2000-04-26
CA2238098C (en) 2001-01-30
EP0914821A2 (en) 1999-05-12
JPH11507946A (ja) 1999-07-13
AU1085997A (en) 1997-06-19
DE69606882D1 (de) 2000-04-06
US5763496A (en) 1998-06-09
GR3033067T3 (en) 2000-08-31
CA2238098A1 (en) 1997-06-05
JP2003176224A (ja) 2003-06-24
WO1997019679A3 (en) 1997-08-28
ATE189957T1 (de) 2000-03-15

Similar Documents

Publication Publication Date Title
ES2144792T3 (es) Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis.
Lowell et al. In vitro evaluation of endothelial and smooth muscle function of primary varicose veins
Rakici et al. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
ES2136618T3 (es) Cicatrizacion de heridas.
MY138301A (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
NO20073456L (no) Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling
HUP0303923A2 (hu) Szterin abszorpció inhibitor(ok)kombinációi kardiovaszkuláris szerekkel vaszkuláris kondíciók kezelésére és a kombinációt tartalmazó készítmények
AR002254A1 (es) Formulacion antitrombotica y procedimiento para su manufactura
AR007989A1 (es) Un metodo para reducir el nivel de lipidos en el suero, colesterol y/o trigliceridos y tratar enfermedades relacionadas en una especie de mamiferosmediante una combinacion de un inhibidor de las proteinas de transferencia de trigliceridos microsomales (mtp) y otro agente de reduccion del colesterol, y
AR039416A1 (es) Un metodo para prevenir y/o tratar el rechazo cronico en un organo o un tejido transplantado
ES2090244T3 (es) Procedimiento para prevenir, estabilizar u ocasionar la regresion de la aterosclerosis usando una combinacion de un medicamento para disminuir el colesterol y un inhibidor de la ace.
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
CO5611156A2 (es) Metodos de tratamiento de enfermedad vascular
DE69327263D1 (de) Verwendung des Gewebefaktor-Inhibitors zur Herstellung eines Arzneimittels gegen Mikrogefässthrombose
ES2169128T3 (es) Procedimientos para el tratamiento de enfermedades utilizando celulas de sertoli y aloinjertos o xenoinjertos.
AR031117A1 (es) Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica
MX9606503A (es) Inhibidores de pla2 y su uso para la inhibicion de la absorcion del colesterol interno.
Koga et al. Pathological and angiographic regression of coronary atherosclerosis by LDL-apheresis in a patient with familial hypercholesterolemia
ES2051675T3 (es) Inhibidores de protorfirinogeno y su uso en composiciones para detectar y tratar tumores.
NO20000087L (no) Behandling av inflammatoriske sykdommer i tarmen og urinblære
RU95103436A (ru) Способ замедления прогрессирования атеросклероза коронарных артерий с помощью правастатина
Pipili et al. Angiotensin converting enzyme activity is present in the endothelium‐denuded aorta
DE69716341D1 (de) Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 861070

Country of ref document: ES